All In Biotech

Drug Trial Radar · NCT06846398

A Phase 2 in Adult Subjects With Hereditary Angioedema

A Phase 2, Open-label, Multicenter Study to Assess the Efficacy and Safety of BW-20805 in Adult Subjects With Hereditary Angioedema

Last checked: Nov 20, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

25

Actual

Start

Feb 28, 2025

Primary completion

Jun 30, 2026

Study completion Mar 30, 2028

Sponsor

Sponsor type
Industry
First posted
Feb 26, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A Phase 2 in Adult Subjects with Hereditary Angioedema

Conditions

  • Hereditary Angioedema (HAE)

Interventions

  • BW-20805Drug

    SC administrations of BW-20805 600 mg on Day1 to Day673

  • BW-20805Drug

    SC administrations of BW-20805 300 mg every 24 weeks on Day1 to Day169;Day337 to Day673

  • BW-20805Drug

    SC administrations of BW-20805 300 mg every 12 weeks on Day 1 to Day 589

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. To determine the prophylactic effect of in HAE attack rate.Time frame: from baseline to Day169

Locations

18 sites in 6 countries. Site status is shown where the registry gives one.

  • Institute for Asthma and Allergy - Wheaton

    Silver Spring, Maryland

  • Washington University School of Medicine

    St Louis, Missouri

  • Duke University Medicine Center

    Durham, North Carolina

  • Penn State Milton S. Hershey MC - Penn State

    Hershey, Pennsylvania

  • Inova Clinical Trials and Research Center

    Falls Church, Virginia

  • Peking Union Medical College Hospital

    Beijing, Beijing Municipality, China

  • The First Hospital of Lanzhou University

    Lanzhou, Gansu, China

  • Tongji Hospital, Tongji Medical College of Huazhong University of Science and Technology

    Wuhan, Hubei, China

  • Yantai Yuhuangding Hospital

    Yantai, Shandong, China

  • West China Hospital, Sichuan University

    Chengdu, Sichaun, China

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, China

  • Universitätsmedizin der Johannes Gutenberg

    Mainz, Rhineland-Palatinate, Germany

  • Charité - Universitätsmedizin Berlin

    Berlin, State of Berlin, Germany

  • Azienda Ospedaliero Universitaria Policlinico G. Rodolico San Marco - Ospedale San Marco

    Catania, Catania, Italy

  • Azienda Ospedaliero-Universitaria Careggi

    Florence, Florence, Italy

  • Azienda Ospedale - Universita di Padova

    Padova, PD, Italy

  • SP ZOZ Szpital Uniwersytecki w Krakowie

    Krakow, Lesser Poland Voivodeship, Poland

  • Hospital Universitario Virgen del Rocío

    Seville, Sevilla, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.